A phase I clinical trial of vorinostat in combination with sFULV2 in patients with refractory solid tumors

MLA

Gerald J. Fetterly, et al. “A Phase I Clinical Trial of Vorinostat in Combination with SFULV2 in Patients with Refractory Solid Tumors.” Journal of Clinical Oncology, vol. 27, May 2009, p. 4083. EBSCOhost, https://doi.org/10.1200/jco.2009.27.15_suppl.4083.

APA

Gerald J. Fetterly, Robert B. Diasio, Igor Espinoza-Delgado, J. Phelan, B. Yirinec, Merrill J. Egorin, Marwan Fakih, Lakshmi Pendyala, Mary Ellen Ross, & Z. Kramer. (2009). A phase I clinical trial of vorinostat in combination with sFULV2 in patients with refractory solid tumors. Journal of Clinical Oncology, 27, 4083. https://doi.org/10.1200/jco.2009.27.15_suppl.4083

Chicago

Gerald J. Fetterly, Robert B. Diasio, Igor Espinoza-Delgado, J. Phelan, B. Yirinec, Merrill J. Egorin, Marwan Fakih, Lakshmi Pendyala, Mary Ellen Ross, and Z. Kramer. 2009. “A Phase I Clinical Trial of Vorinostat in Combination with SFULV2 in Patients with Refractory Solid Tumors.” Journal of Clinical Oncology 27 (May): 4083. doi:10.1200/jco.2009.27.15_suppl.4083.